US healthcare giant Johnson & Johnson’s subsidiary Janssen-Cilag yesterday announced today new results from the Phase II RedirecTT-1 study evaluating the investigational combination of Talvey ...

Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...

As part of implementing President Trump’s Executive Order No. 14273, Lowering Drug Prices by Once Again Putting Americans First, US the Federal Trade Commission (FTC) and the Justice Department of ...

With exports valued at 105.5 billion Swiss francs ($130.2 billion) and a 38.5% share of total exports, the pharmaceutical ...

A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...

Formed in 2024 by ADQ, a sovereign wealth fund, Arcera consolidates several pharmaceutical businesses, including Acino ...

Notable research news last week included US biopharma Avidity Biosciences announcing a positive update on its muscular ...

The US Food and Drug Administration (FDA) has notified KalVista Pharmaceutical that it will not meet the Prescription Drug ...

The International Finance Facility for Immunization (IFFIm) has announced the settlement of its £300 million ($407 million), ...

US immunology specialist Celldex was trading 5% higher midday Friday, following on from 10% gains on Thursday.

Anglo-Swedish pharma major AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC ...